Boston Celtics Sale and Pharmaceutical Patents

6min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

The chapter covers the potential sale of the Boston Celtics NBA franchise for over $5 billion, driven by media rights and recent NBA success. It also delves into the FTC's investigation into pharmaceutical company Teva Pharmaceuticals over alleged bogus patents on asthma and COPD inhalers to maintain high prices in the US.

Episode 356: Neal and Toby dive into the EU’s latest campaign against Big Tech, namely Meta and Apple, alleging these companies are stifling competition in Europe. Then, the Boston Celtics are just coming off an NBA championship, but that doesn’t stop the owners from selling the team. Plus, the FTC is looking into ‘junk’ patents from pharmaceutical companies meant to prevent generic drug makers from cutting into their business. Meanwhile, Roaring Kitty is at it again, this time making movements for Chewy.com. Next, Toby examines the trend of ‘romantasy’ novels that are flying off the shelves. Lastly, China might have a way around high US tariffs: golf carts.

Get your Morning Brew Daily Mug HERE: https://shop.morningbrew.com/products/morning-brew-daily-mug?utm_medium=youtube&utm_source=mbd&utm_campaign=mug

Listen to Morning Brew Daily Here: https://link.chtbl.com/MBD

Watch Morning Brew Daily Here: https://www.youtube.com/@MorningBrewDailyShow

Learn more about your ad choices. Visit megaphone.fm/adchoices